Sarah Cannon Research Institute

Publications

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong , Marwan Fakih , John H. Strickler +31 more

Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-rela...

2020 New England Journal of Medicine 1570 citations

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Ferdinandos Skoulidis , Bob T. Li , Grace K. Dy +23 more

In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Fund...

2021 New England Journal of Medicine 1567 citations

Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)

Edward B. Garon , Leena Gandhi , Naiyer A. Rizvi +17 more

2014 Annals of Oncology 72 citations

Institution Info

Type: education
Country: GB
Publications: 3
Citations: 3,209

External Links

Identifiers

ROR: https://ror.org/03cp5cj42

Publications

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)

Institution Info

External Links

Identifiers